Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jill Dickerson

Clinical Nurse Specialist, Medical-Surgical San Antonio, TX Nurse Practitioner

NPI 1730201195 CMS profile 10922402

7700 Floyd Curl Dr, San Antonio, TX 78229

Open in the dashboard

General payments

$5,255

135 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jill Dickerson of San Antonio, TX is reported in the CMS Open Payments database as having received $5,255 across 135 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Clinical Nurse Specialist, Medical-Surgical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,765 45
2024 General $1,202 37
2023 General $881 24
2022 General $533 11
2021 General $874 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jill Dickerson
  • Clinical Nurse Specialist, Medical-Surgical median
  • Middle half of Clinical Nurse Specialist, Medical-Surgical
  • National median

In program year 2025, general payments to Jill Dickerson were reported at $1,765. Among 59 Clinical Nurse Specialist, Medical-Surgical profiles paid that year, the median was $165 and the middle half received between $54 and $254.

Show as a table
Year Jill Dickerson Clinical Nurse Specialist, Medical-Surgical median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $874 $214 $58–$714 $132
2022 $533 $153 $29–$560 $149
2023 $881 $119 $27–$460 $160
2024 $1,202 $124 $52–$304 $164
2025 $1,765 $165 $54–$254 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $743 23 payments
  2. AstraZeneca Pharmaceuticals LP $603 9 payments
  3. AbbVie, Inc. $596 24 payments
  4. Astellas Pharma US Inc $425 10 payments
  5. Genzyme Corporation $353 7 payments
  6. Lilly USA, LLC $309 3 payments
  7. EMD Serono, Inc. $263 3 payments
  8. Novartis Pharmaceuticals Corporation $242 12 payments
  9. Pharmacyclics LLC, An AbbVie Company $229 7 payments
  10. Merck Sharp & Dohme Corporation $155 7 payments
  11. Other $1,339 30 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,208 124 payments
  2. Education $1,047 11 payments
Products named General payments · program years 2021–2025
  1. IMBRUVICA $561 21 payments
  2. EPKINLY $521 24 payments
  3. SARCLISA $244 6 payments
  4. DARZALEX $209 4 payments
  5. TECVAYLI $207 10 payments
  6. LIBTAYO $175 2 payments
  7. RYBREVANT $137 3 payments
  8. ELITEK $135 3 payments
  9. CARVYKTI $131 2 payments
  10. Bavencio $119 1 payment
  11. Other $2,542 81 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

135 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Medical-Surgical in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record